A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

Inclusion Criteria Patients must have: * HIV infection OR diagnosis of AIDS. * Diffuse oral candidiasis, symptomatic or asymptomatic, that is resistant to fluconazole. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current symptoms of esophageal candidiasis unless there are negative endoscopic visualization and biopsy for Candida or related yeasts. * Perioral lesions only (e.g., angular stomatitis, perleche). * Inability to swish and swallow oral solution. * Inability to tolerate further oral therapy for thrush. Concurrent Medication: Excluded: * Fluconazole. * Itraconazole. * Ketoconazole. * Flucytosine. * Intravenous amphotericin or other non-study formulations. * Nystatin. * Clotrimazole. * Other investigational antifungal agents. * Systemic cytotoxic chemotherapy for malignancy. Concurrent Treatment: Excluded: * Radiation therapy to the mouth, neck, or chest. Patients with the following prior conditions are excluded: * Esophageal candidiasis, proven or presumptive, occurring since fluconazole failure. * Successful treatment of thrush with fluconazole at \<= 200 mg/day after original treatment failure. * History of oral candidiasis that recurred or persisted despite IV amphotericin B given once or more weekly. * History of anaphylaxis to amphotericin B. * History of hypersensitivity to components in amphotericin B oral suspension. Prior Medication: Excluded within 6 weeks prior to study entry: * Cytotoxic therapy for malignancy. * Corticosteroids at higher than replacement doses.